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Some protein pharmaceuticals from Chinese medicine have been developed to treat cardiovascular diseases,
genetic diseases, and cancer. Bioactive proteins with various pharmacological properties have been successfully
isolated from animals such as Hirudo medicinalis (medicinal leech), Eisenia fetida (earthworm), and Mesobuthus
martensii (Chinese scorpion), and from herbal medicines derived from species such as Cordyceps militaris,
Ganoderma, Momordica cochinchinensis, Viscum album, Poria cocos, Senna obtusifolia, Panax notoginseng, Smilax
glabra, Ginkgo biloba, Dioscorea batatas, and Trichosanthes kirilowii. This article reviews the isolation methods,
molecular characteristics, bioactivities, pharmacological properties, and potential uses of bioactive proteins
originating from these Chinese medicines.Background
The therapeutic potential of proteins from Chinese medi-
cine (CM) has not realized without extensive research.
Nevertheless, according to a report from BCC Research
LLC. in October 2013, the global market for protein phar-
maceuticals was predicted to be $136.7 billion in 2013 and
to increase to $179.1 billion in 2018, with an average an-
nual growth rate of approximately 5.6% from 2013 to 2018
[1]. Many protein pharmaceuticals are available for treat-
ing rheumatoid arthritis, coronary artery thrombosis, mul-
tiple sclerosis, and chronic lymphocytic leukemia [2-4].
Quality control of Chinese medicinal herbs is a chal-
lenge because the therapeutic effects of medicinal herbs
are subject to by different factors, such as geographical
constraints, soil mineral content, temperature, and humid-
ity. Moreover, guidelines for quality control are not readily
available. The 2002 guidelines of the European Agency for
the Evaluation of Medicinal Products for good agricultural
practice does not include a standardization for materials
of herbal origin [5]. However, protein or peptide pharma-
ceuticals derived from CM can be produced through
recombinant technology, which can minimize batch-to-* Correspondence: stephens@hku.hk
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reproduction in any medium, provided the orbatch variations in quality [6]. Additionally, drug delivery
systems, such as polyethylene glycol (PEG) and nanocar-
riers, could promote the clinical efficacy of protein drugs
from CM [7,8].
This article aims to review the bioactive proteins and
peptides isolated from CM with potential for clinical use.Methodology
A variety of databases, including Google Scholar/Google,
PubMed, Science direct, CINAHL Plus, Cochrane Library,
Global health, ISI Web of Knowledge, Chinese database
CNKI, CQVIP, and CJFD, were searched to get the infor-
mation about protein drugs derived from Chinese medi-
cine with the following key words: “Chinese medicine”,
“natural products” together with “protein”, “peptide”, “pro-
tein pharmaceuticals”, “peptide pharmaceuticals” or “pro-
tein drugs”. Furthermore, information on the website of
WHO was also collected. For the bioinformatics informa-
tion of protein, the protein structure, sequence alignment
or both, were obtained from the Molecular Modeling
Database (MMDB) and Conserved Domain Database
(CDD) on the website of NCBI by searching their scientific
names of species and their protein names. All data were
further analyzed to obtain the information about the
current progress in research on promising protein/peptide
drugs isolated from CM.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Raw and fresh CM materials, rather than dried, processed,
or powdered materials, are often used to obtain bioactive
peptides to prevent protein denaturation and degradation
from processing [9,10]. Some isolated proteins have been
approved by the Food and Drug Administration (FDA) of
the United States for clinical use or clinical trials (Table 1).
Animal proteins and peptides
Hirudin from Hirudo spp. (leech)
Hirudin, from the saliva of Hirudo spp., was used in CM
to enhance blood (xue) circulation [11]. Hirudin was a po-
tent natural inhibitor of thrombin [12] via formation of a
hirudin-thrombin complex [13,14]. Although hirudin was
isolated and purified from a complex salt-containing solu-
tion with hydrophobic chromatography [15], it was diffi-
cult to extract large amounts of hirudin from natural
sources. Hirudin is approximately 7.1 kDa and is com-
posed of 65 amino acids, including a compact N-terminal
domain containing three S-S bonds and a C-terminal do-
main that is disordered in un-complexed hirudin [16,17].
Figure 1 illustrates the interaction of hirudin with napsa-
gatran [13,18].
In contrast to antithrombin III, hirudin inhibited throm-
bin [13], for treating blood coagulation disorders such as
venous thrombosis, coronary thrombosis, and stroke [19].
Recombinant or synthetic hirudin would be of great clin-
ical value because only low yields of hirudin could be ex-
tracted from leeches. Bivalirudin is a 20-amino-acid-long
synthetic peptide engineered as an analogue of hirudin
and has advantages over heparin [20]. The required dosage
of bivalirudin was lower, and the anticoagulation mechan-
ism did not depend on intrinsic factors, as was the case of
heparin [21]. Bivalirudin was approved by the FDA in De-
cember 2000 and was frequently used as an anticoagulant in
percutaneous coronary intervention [22,23]. A pharmacoki-
netic study of recombinant hirudin with chromogenic sub-
strate assay and ELISA demonstrated that its half-life in the
plasma in male Sprague Dawley rats was less than 1 h [24].
Additionally, hirudin possessed anti-proliferative activity
toward human ovarian cancer cells and tongue squamous
cell cancer cells with a synergistic effect with adriamycin
in vitro [25-27].
Fibrinolytic enzymes from Eisenia fetida (earthworm)
Eisenia fetida (earthworm) was used in CM as an antipyr-
etic and anesthetic for treating asthma and hypertension
[28]. Ten fibrinolytic enzymes categorized into four groups
had been isolated from Eisenia fetida [9]. The total number
of fibrinolytic enzymes from Eisenia fetida was controver-
sial, because the chemical charactersticis, including the
full-length amino acid sequences, were not well studied
[29]. Seven fibrinolytic enzymes, EFE-a, EFE-b, EFE-c,
EFE-d, EFE-e, EFE-f, and EFE-g, were isolated andpurified from lyophilized crude powder of earthworm fi-
brinolytic enzymes by ATKA Purifier, FPLC, and relative
pre-packing chromatography columns [30]. These en-
zymes were crystallized with the hanging-drop vapor-
diffusion method [30].
EFE-a, d, and e are approximately 2.4 kDa with iso-
electric points (pI) of 3.46, 3.68, 3.62, respectively [30].
EFE-b, c, and g are approximately 3.0 kDa with pI of
3.50, 3.50, 3.46, respectively [30]. EFE-f has a molecular
weight of about 2.3 kDa with a pI of 3.94 [30]. Figure 2
shows the interaction of a fibrinolytic enzyme with N-
acetyl-beta-D-glucosaminylamine [18,31,32].
Fibrinolytic enzymes exhibited different fibrinolytic
activities. EFE-a possessed fibrinolytic activity, with
plasminogen-activating activity, which was not present
in the other fibrinolytic enzymes [30]. Moreover, earth-
worm fibrinolytic enzymes exhibit antitumor activity
against several hepatoma cell lines in vitro and in vivo [33],
which were potential therapeutic enzymes for hepatomas
[34]. After chemically conjugated with human serum albu-
min fragments, the enzymes lost their antigenicity and ac-
quired resistance to inactivation by protease inhibitors [35].
However, maintenance of enzymatic activity within the
body and cleave-site specificity of the enzyme were critical
challenges to the practical use of earthworm fibrinolytic
enzymes [34].
An antiepilepsy protein (AEP) from Mesobuthus martensii
(Chinese scorpion)
Scorpions, especially their tails, were used in CM for the
treatment of convulsion and epilepsy [36]. An antiepilepsy
protein (AEP) was isolated from the venom of the Chinese
scorpion Mesobuthus martensii by chromatography, in-
cluding CM-Sephadex C-50 chromatography, gel filtration
on Sephadex G-50, and DEAE-Sephadex A-50 chromatog-
raphy. The homogeneity of AEP was demonstrated using
pH 4.3 polyacrylamide-disc-gel electrophoresis, focusing
electrophoresis, and SDS/polyacrylamide-disc-gel electro-
phoresis [37]. AEP is an 8.3-kDa peptide composed of 61
amino acids, and is derived from an 85-amino-acid pre-
cursor. The mature protein contains eight cysteine resi-
dues that form four disulfide bonds [38].
AEP exhibited antiepileptic activity by binding to the
presynaptic membrane protein synaptosomal-associated
protein 25 and the glutamate receptor N-methyl-D-aspar-
tate. Hemorrhagic and toxic activities were not detected in
AEP [39]. AEP (28 mg/kg) slightly decreased heart rate
in mice without toxicity [37]. The AEP relieved seizures
induced by the coriaria lactone without reported side
effects in mice [38,40]. The gene encoding AEP was suc-
cessfully cloned, sequenced, and expressed in a eukaryotic
system, providing a rapid method for producing the pro-
tein for further mechanistic study [38,39]. Figure 3 shows
the alignment of conserved domains in AEP [41].
Table 1 Bioactive proteins isolated from Chinese medicine and their reported pharmacological effects
CM Pharmacologically active proteins or peptides Pharmacological effects
Peptides/protein from medicinal animals
Hirudo spp. (Leeches) Hirudin Anti-coagulation activity through inhibition of thrombin activity [13,14]
Anti-proliferative activity toward human ovarian and
tongues squamous cancer cells [24-27]
Eisenia fetida (Earthworm) Earthworm fibrinolytic enzyme Anti-cancer activity against hepatoma in vitro and in vivo [33]
Mesobuthus martensii (Chinese scorpion) Anti-epilepsy protein (8.3 kDa) Anti-epilepsy activity in mice in vivo [36,37]
Peptides/Protein from medicinal fungi
Cordyceps militaris Lectin designated as CML (31 kDa) Haemagglutinating activity in mouse and rat erythrocytes
Mitogenic activity on mouse splenocytes [43]
Cordymin (10.9 kDa) Anti-fungal activity through inhibition of mycelial growth in vitro [44]
Inhibitory effect on HIV-1 reverse transcriptase in vitro [42]
Anti-cancer activity against MCF-7 breast cancer cells in vitro [42]
Protease designated CMP (12 kDa) Anti-fungal activity in vitro [44]
Anti-cancer activity against MCF-7 breast cancer cells
and bladder cancer 5637 cells in vitro [44]
Ganoderma spp. (Ling Zhi) Ling Zhi-8 (12.4 kDa protein) Immuno-modulatory activity through inducing maturation
of human monocyte-derived dendritic cells and stimulating
IL2 and IFN-γ secretion from CD4+ and CD8+ T cells [52], [53]
Anti-cancer activity against lung carcinoma
cell growth in vitro and in vivo [55,56]
Lectin (a 18-kDa protein) Haemagglutinating activity and mitogenic activity
towards BALB/c mouse splenocytes [49]
Anti-cancer activity against leukemia (L1210 and M1)
cells and hepatoma (HepG2) cells [54]
Poria cocos (Schw.) Wolf P. cocos immunomodulatory protein (35.6 kDa) (PCP) Immunomodulatory activity through activating
mouse peritoneal macrophages (RAW 264.7) [60]
Peptides/proteins from medicinal herbs
Viola tricolor Cyclotides Anti-cancer activity against human cancer cells U251,
MDA-MB-231, A549, DU145 and BEL-7402 in vitro [63]
Momordica cochinchinensis seeds (Mubiezhi) Cochinin B (28 kDa ribosome inactivating protein) Anti-cancer activity against human cervical epithelial carcinoma
(HeLa), human embryonic kidney (HEK293) and human small
cell lung cancer (NCI-H187) cell lines in vitro [69]
MCoCC-1 (a 33 amino acid long peptide) Anti-cancer activity against human melanoma
cell line (MM96L) in vitro [67,71]
Chymotrypsin inhibitor designated as MCoCI (7.5 kDa) Anti-oxidative activity through activation of glutathione-S-transferase
and superoxide dismutase in vitro [71]
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Table 1 Bioactive proteins isolated from Chinese medicine and their reported pharmacological effects (Continued)
Immunomodulatory activity through stimulating the proliferation
of mouse splenocytes, splenic lymphocytes, bone marrow
cells and macrophages in vitro [67]
Viscum album (Chinese mistletoe) Lectin designated as CM-1 (55 kDa) Anti-cancer activity against CLY colon cancer cells and HT-29
colorectal cancer cells in vivo and in vitro through down-regulation
of micro-RNA miR-135a & b expression [73]
Lectin designated as ACML-55 Immunomodulatory activity through enhancing both antigen
specific activation and proliferation of CD4+ and CD8+ T cells
as well as number of tumor antigen specific CD8+ T cells [74]
The seeds of Senna obtusifolia Novel protein (19.7 kDa) Inhibitory effect on cholesterol biosynthesis in
Chinese hamster oocytes in vitro [78]
Narcissus tazetta var. chinenesis Narcissus tazetta lectin (26 kDa) Antiviral activity against human syncytial virus
(RSV), influenza A and influenza B viruses [80]
Immunopotentiating activity through inducing gene
expression of IL-1βand TNF-α in splenocytes
and macrophages in vivo [81]
Smilax glabra rhizomes (Tufuling) Smilaxin (30 kDa) Immuno-stimulating activity in vitro [83]
Anti-cancer activity against MBL2 and PU5 cells in vitro [83]
Inhibitory effect on HIV-1 reverse transcriptase in vitro [83]
Ginkgo biloba seeds (Yinxing) Ginkbilobin (13 kDa) Anti-fungal activity against Botrytis cinerea, Mycosphaerella
arachidicola, Fusarium oxysporum, Rhizoctonia solani,
and Coprinus comatus [85]
Antibacterial activity against Staphylococcus aureus,
Pseudomonas aeruginosa, and Escherichia coli [85]
Inhibitory effect on HIV-1 reverse transcriptase [85]
Immuno-modulatory activity through inhibiting
proliferation of murine splenocytes [85]
Dioscorea batata Dioscorin (32 kDa) Carbonic anhydrase activities [90]
Trypsin inhibitory activities [90]
Potential airway protective effects on
A549 human airway epithelium cells [91]
Anti-oxidant properties reflected from DPPH
and hydroxyl radicals scavenging effects [93]
Immuno-modulatory activity in vitro and in vivo [94,95]
Trichosanthes kirilowii Trichosanthin (247 amino acid long peptide) Anti-HIV activity through inhibition of serum HIV-1 p24 antigen levels
and increase CD4+ T cell count in HIV-1 infected patients [108,109]
Antiviral activity against hepatitis B virus [110,111]
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Figure 1 Molecules and interactions of hirudin. H, chain H of human thrombin; I, hirudin variant-1; L, chain L of Human thrombin. 1, Napsagatran.
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Lectin and cordymin from Cordyceps militaris
C. militaris is a less expensive substitute for the mushroom
Cordyceps sinensis (Dong Chong Xia Cao) with different
pharmacological properties, including hemagglutinating ac-
tivity, antifungal properties, and antiproliferative properties
[42-44].
A lectin (CML) was isolated and purified from the crude
protein extract of C. militaris by gel-filtration chromatog-
raphy on a Sephadex G-75 affinity fetuin-agarose column
and dialysis [43]. Purified cordymin was obtained with
ion-exchange chromatography of the aqueous extract on
SP-Sepharose and Mono S, and gel filtration on Superdex
75 by fast protein liquid chromatography (FPLC) [42]. An-
other anti-fungal and anti-cancer C. militaris protein
(CMP), was isolated by anion-exchange chromatography
on a DEAE-Sepharose column [44].(A) (B)
Figure 2 Molecules and interactions of fibrinolytic enzyme. (A), fibrino
chain A of fibrinotic enzyme component B; B, chain B of fibrinotic enzyme
alpha-L-Fucose; 3, Mg2+; 4, sulfate ion and alpha-D-mannose.CML is approximately 31 kDa and contains the N-
terminal amino acid sequence SYDADXQRVXNDK-
GIXND (the “X” residue could not be identified), which has
low homology compared with the lectins from other mush-
rooms, such as Marasmius oreades, Laetiporus sulphureus
and Polyporus squamosus [43]. Moreover, the secondary
structure of CML contains 27% α-helix, 12% β-sheets, 29%
β-turns, and 32% random-coil structures, which is different
from the lectins isolated from other mushrooms, such as
Marasmius oreades, Laetiporus sulphureus and Polyporus
squamosus [43]. Cordymin is an approximately 10.9-kDa
peptide, isolated from C. militaris, and its N-terminal se-
quence is AMAPPYGYRTPDA which is not similar to
other peptides in the GeneBank database [42]. Another iso-
lated peptide, C. militaris protein (CMP) is a 12-kDa pep-
tide and its pI is 5.1 [44]. Moreover, two parts of the CMP
sequence (VSXXGDSGVGGN and NAFNDYTFK) possesstic enzyme component A; (B), fibrinotic enzyme component B; A,
component B; 1, N-Acetyl-beta-D-glucosaminylamine; 2,
Figure 3 Alignment of anti-epilepsy peptide conserved domain in Conserved Domain Database (CDD) of NCBI. The entry used for query
was gi|9886761|gb|AAG01571.1|. Aligned residues are in upper case, unaligned residues in lower case, and gaps are displayed as dashes. Red
letters indicate highly conserved residues and blue letters indicates less conserved residues Unaligned (lower case) residues are displayed in grey.
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amoeba histolytica and exodeoxyribonuclease V alpha chain
from Haemophilus influenza [44].
CML demonstrated hemagglutinating activity in
mouse and rat erythrocytes by specifically binding sialo-
glycoproteins, and exerted mitogenic activity on mouse
splenocytes [43]. Cordymin inhibited not only mycelial
growth of numerous fungi, including Bipolaris maydis,
Rhizoctonia solani, and Mycosphaerella arachidicola, but
also HIV-1 reverse transcriptase and the proliferation of
MCF-7 breast cancer cells [42]. CMP could be inhibited
by serine protease inhibitors, exhibited an antifungal ef-
fect on the growth of Fusarium oxysporum at a mini-
mum concentration of 1.6 μM, and had antiproliferative
effects on human breast cancer MCF-7 cells (IC50 of
9.3 μM) and bladder cancer 5637 cells (IC50 of 8.1 μM)
[44]. Cordymin prevented osteopenia in diabetic rats by
significant up-regulation of bone mineral content and
bone mineral density [45].
Ling Zhi-8 and lectin from Ganoderma
Ganoderma (Ling Zhi) contains a rich content of bio-
active constituents and exhibits diverse pharmacological
effects, such as anticancer activity, immunomodulatory ac-
tivity, hypoglycemic action, and hepatoprotection [46].
Moreover, Ganoderma capense (Lloyd) Teng was used to
tonify the body and improve mental function [47]. Several
bioactive peptides have been purified from Ganoderma,
including Ling Zhi-8 (LZ-8) and Ganoderma capense lec-
tin (GCL) [46,48].
LZ-8 (12.4-kDa) was isolated from Ganoderma lucidum
by Sephadex G-75 column and DEAE-Sephadex A-25 col-
umn chromatography, and dialysis, and was characterized
by electrophoretic techniques [49,50]. Additionally, an 18-kDA lectin from Ganoderma capense (Lloyd) Teng, GCL,
was purified by column chromatography on Q-Sepharose
and Mono S and gel filtration on a Superdex 75 HR 10/30
column with an AKTA Purifier [49,50].
LZ-8 is a 12-kDa polypeptide consisting of 110 amino
acid residues with an acetylated amino terminus [49,50].
The molecular mass of GCL is 18 kDa, and its N-terminal
sequence displays slight similarity to a lectin from Gano-
derma lucidum and fungal immunomodulatory proteins
from Flammulina velutipes, Volvariella volvacea [49,50].
The crystal structure of LZ-8 (Figure 4) supplies a basis to
study its bioactive function [18,51]. The C-terminal FNIII
domain possessed the immunoglobulin-like β-sandwich
fold to recognize its target including cytohormones,
cell adhesion molecules, cytokine receptors, molecular
chaperones and carbohydrate binding domains [51].
Recombinant LZ-8 (rLZ-8) protein induced maturation
of human monocyte-derived dendritic cells, which was in-
volved in initiating an antigen-specific T lymphocyte re-
sponse, by activating the NFκB and MAPK pathways [52].
rLZ-8 also stimulated CD4+ and CD8+ T cells to secrete
IL2 and IFN-γ [53]. GCL exhibited hemagglutinating activ-
ity, mitogenic activity toward BALB/c mouse splenocytes,
and antiproliferative activity toward leukemia (L1210 and
M1) cells and hepatoma (HepG2) cells [54]. rLZ-8 could
activate dendritic cells via TLR 4 to strength the effective-
ness of anti-cancer vaccine [55]. LZ-8 prohibited lung car-
cinoma cell growth in vitro and in vivo by regulating p53
[56], and rLZ-8 promoted endoplasmic reticulum stress
and the ATF4-CHOP pathway to induce cell death of
SGC-7901 human gastric cancer cells via autophagy
in vitro [57]. Moreover, rLZ-8 enhanced the immune re-
sponse and increased the amount of white blood cells to
relieve cyclophosphamide-induced leukopenia [58].
Figure 4 Crystal structure of LZ-8. A, Chain A of LZ-8; B, Chain B of LZ-8.
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Poria cocos (Fu Ling) reportedly possessed anti-aging,
anticancer, and immunomodulatory properties [59]. An
immunomodulatory protein (PCP) was isolated and puri-
fied from the dried sclerotium of P. cocos (Schw.) Wolf
with DE-52 cellulose and gel-filtration chromatography,
and was characterized by chromatography and electro-
phoresis [60]. PCP (35.6 kDa) is a disulfide-linked hetero-
dimeric glycoprotein consisting of 14.3 and 21.3 kDa
subunits with N- and O-glycosylation [60]. The full-length
cDNA sequence of PCP has 807 base pairs and the coding
region is 579 base pair encoded 194 amino acids which
provides an opportunity to express the recombinant [61].
PCP stimulated mouse peritoneal macrophages (RAW
264.7) by interacting with toll-like receptor 4 and subse-
quently activating the NFκB signaling pathway [60]. Oral
administration of PCP reduced the production of serum
total IgG1 and OVA-specific IgG1, as well as up-regulated
the serum OVA-specific IgG2a and splenic Th1-related
cytokine and down-regulated IL-4 and IgE levels in atopic
dermatitis mice [61]. Further studies on PCP will elucidate
its modulatory capacity to reveal the pharmaceutical
potential and clinical value.Figure 5 Crystal structure of cyclotides from viola tricolor.Herbal proteins and peptides
Cyclotides (VTCs) from Viola tricolor
Viola tricolor was used in CM for heat (re) dissipation,
detoxification, and cough relief [62]. Recently, 14 cyto-
toxic cyclotides (VTCs) were purified and characterized
from dry whole V. tricolor by the solvent extraction
technique, column chromatography with macroporous
resin (D 101), polyamide (100–200 mesh), reverse phase
C18 (40–63 μm), and Sephadex LH-20 (25–100 μm),
thin layer chromatography, and high performance liquid
chromatography [63]. Additionally, TLC was used to de-
tect the products during the procedure [63].Cyclotides are disulfide-rich proteins that contain a
combination of a head-to-tail cyclized backbone and a
knotted arrangement of three conserved disulfide
bonds that make up a cyclic cystine knot motif [63].
Figure 5 displays the crystal structure of cyclotides
from Viola tricolor [18,64]. Isolated cyclotides exhib-
ited a cytotoxic effect against human cancer cells
U251, MDA-MB-231, A549, DU145, and BEL-7402
[63] and the U-937 GTB and RPMI-8226/s cell lines
[65]. Cyclotides exhibited anticancer, anti-HIV, or
hemolytic activity in vitro [66]. Cyclotides are smaller
than most natural proteins, such as nebrodeolysin, and
their high stability makes them particularly beneficial
to drug design [66].
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cochinchinensis seeds
The seeds of Momordica cochinchinensis (Mubiezhi) were
used as an anti-inflammatory agent to treat hemorrhoids
and hemangiomas [67,68]. Several bioactive proteins were
isolated and purified from M. cochinchinensis, including
ribosome-inactivating protein cochinin B, peptide MCoCC-
1, and a chymotrypsin inhibitor McoCI by ammonium sul-
fate precipitation, cation-exchange chromatography on SP
Sepharose column, and size-exclusion chromatography on
Superdex 75 column with FPLC [69].
The MCoCC peptides were purified from an extract of
driedM. cochinchinensis seeds by a series of RP-HPLC pu-
rifications on Phenomenex C18 columns [68]. Similarly,
McoCI was isolated from M. cochinchinensis (Lour) seeds
by dialysis, chymotrypsin-Sepharose 4B column chroma-
tography and reversed-phase HPLC [70].
Cochinin B has a molecular weight of 28 kDa and the
N-terminal sequence is DVSFDMSTASTESYKKFIAD,
which displays 45–60% identity to other type I RIPs in the
Cucurbitaceae family recorded in GenBank [69]. MCoCC-1
and MCoCC-2, which are approximately 7.5 k Da, have
partial sequences of 33 and 32 amino acid residues, respect-
ively, which differ only in two residues. They are also Cys-
rich peptides with a cystine knot motif [68]. Figure 6 shows
the crystal structure of MCoCC-1 from M. cochinchinensis
[18,68].
Cochinin B, a ribosome-inactivating protein, exhibited
strong anticancer activity against human cervical epithelial
carcinoma (HeLa), human embryonic kidney (HEK293),
and human small cell lung cancer (NCI-H187) cell linesFigure 6 Crystal structure of MCoCC-1 from
momordica cochinchinensis.[69]. MCoCC-1, exhibited cytotoxic effects against human
melanoma cell line MM96L and was nonhemolytic [68].
McoCI, a 7.5-kDa antioxidative and immunomodulatory
potato I family chymotrypsin inhibitor, reversed oxidative
injury in t-BHP-challenged rat hepatocytes via the antioxi-
dative activity of glutathione-S-transferase and superoxide
dismutase [71]. It stimulated the proliferation of mouse
splenocytes, splenic lymphocytes, bone marrow cells, and
macrophages, and inhibited H2O2 production by macro-
phages and neutrophils [67].
Lectin CM-1 and ACML-55 from Viscum album
Viscum album (Mistletoe) was used as a complementary
anticancer medicinal herb [72]. A mistletoe lectin-I,
designated as CM-1, was isolated from the leaves of V.
album and purified by affinity chromatography and
cation-exchange chromatography [73]. ACML-55 was
isolated by solvent extraction and purified by CM-
Sepharose column chromatography [74].
CM-1, a 55-kDa lectin, down-regulated micro-RNA
miR-135a and miR-b expression, leading to up-regulation
of adenomatous polyposis coli gene expression and at-
tenuation of the Wnt pathway in CLY colon cancer cells
and HT-29 colorectal cancer cells, both in vivo and
in vitro [73]. ACML-55 enhanced both antigen-specific ac-
tivation and proliferation of CD4+ and CD8+ T cells and a
number of tumor antigen-specific CD8+ T cells in colon
cancer cell line CT 26 in BALB/c mice [74]. The number
of natural killer cells and gamma-delta T cells was also ele-
vated, indicating that ACML-55 modulated innate and
adaptive immune responses [74]. The lectin from V.
album activated autophagy to promote the proliferation of
placenta-derived mesenchymal stem cells via upregulation
of type II LC3 and downregulation of phosphorylated
mTOR [75].
A cholesterol-lowering protein from Senna
obtusifolia seed
Senna obtusifolia seeds (Juemingzi) were used in CM to
treat hyperlipidemia and hypertension, and to remove liver
heat (gan re) [76,77]. Moreover, a novel cholesterol-lowering
protein was isolated and purified from S obtusifolia seeds by
gel-filtration and ion-exchange chromatography [78].
This cholesterol-lowering protein is a single protein with
a molecular weight of 19.7 kDa and a pI of 4.8 [78]. N-
terminal amino acid sequence of this peptide, IPYISASFPL-
NIEFLPSE, has no homology with any other protein
sequences in the GeneBank [78]. Its secondary structure has
12.5% α-helix, 55.6% β-sheet, and 31.9% random coil [78].
This cholesterol-lowering protein inhibited cholesterol
biosynthesis in Chinese hamster oocytes [78]. Statins were
commonly used as HMG-CoA reductase inhibitors to re-
duce the blood cholesterol level. However, they had adverse
effects, mainly on muscles but occasionally on nonmuscle
Figure 7 Crystal structure of Ginkbilobin-2 of Ginkgo
biloba seeds.
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safety of the novel protein from Juemingzi must be thor-
oughly evaluated.
Lectin (NTL) from Narcissus tazetta var. chinensis
Narcissus tazetta var. chinensis was an anticancer medi-
cinal herb. N. tazetta lectin, (NTL) was isolated and puri-
fied by various chromatographies, including ion- exchange
chromatography on diethylaminoethyl (DEAE)-cellulose,
affinity chromatography on mannose-agarose, and FPLC-
gel filtration on Superose 12 [80].
NTL has a molecular weight of 26 kDa, and is probably a
dimer with two identical subunits. NTL protein, predicted
by cDNA sequence, contains a mature polypeptide and a
C-terminal peptide extension [80]. Moreover, NTL primary
polypeptide contains three subdomains, each with a con-
served mannose-binding site. NTL is 60–80% identical to
other known monocot mannose-binding lectins [80].
NTL inhibited plaque formation from human syncytial
virus (RSV) and antiviral properties against influenza A
and B [80]. NTL exhibited an immunopotentiating ef-
fect, similar to that of LZ-8, by inducing gene expression
of IL-1β, TNF-α, and nitric oxide synthase in splenocytes
and macrophages in vivo [81].
Smilaxin from Smilax glabra rhizomes
Smilax glabra rhizomes (Tufuling) had antipyretic, de-
toxifying, and diuretic effects and were used in the treat-
ment of brucellosis, syphilis, furunculosis, eczema,
dermatitis, nephritis, cystitis, and mercury and silver poi-
soning [82]. Smilaxin was isolated from fresh S. glabra by
successive column chromatography on DEAE-cellulose,
CM-cellulose, Con A-Sepharose, and Mono S, and FPLC-
gel filtration on Superdex 75 [83]. Smilaxin is a 30-kDa
protein, and the N-terminal sequence of smilaxin is hom-
ologous to few proteins [83].
Smilaxin exhibited immunostimulatory, antiproliferative,
and HIV-1-reverse transcriptase inhibitory activities [83].
Smilaxin specifically stimulated the uptake of [methyl-3H]
thymidine in murine splenocytes, peritoneal macrophages,
and bone marrow cells, but not in MBL2 or PU5 tumor
cells [83]. It also attenuated the activity of HIV-1 reverse
transcriptase with an IC50 of 5.6 μM [83].
Ginkbilobin from Ginkgo biloba seeds
Ginkgo biloba seeds were used in CM for relieving
cough and asthma, reducing phlegm, and leukorrhea,
and treating incontinence [84]. Ginkbilobin was isolated
and purified from G. biloba seeds by dialysis, DEAE-
cellulose column chromatography, Affi-gel blue gel
chromatography, ion-exchange chromatography, and
FPLC-gel filtration [85]. Purified Ginkbilobin-2 was ob-
tained by Sephadex G-50 column and ion-exchange
chromatography [86].Both ginkbilobin and ginkbilobin-2, are ~13-kDa pro-
teins with 108 amino acids, which is the product of a pro-
peptide containing 134 amino acids and a potential signal
peptide (26 residues) with approximately 85% identity to
embryo-abundant proteins from Picea abies and Picea
glauca [87]. The differences in amino acid sequence be-
tween ginkbilobin and ginkbilobin-2 are His10/Cys, Ala17/
Ser, Ala19/Ser, Ala36/Thr, and Ala39/Ser. Ginkbilobin has
two α-helices and a five-stranded β-sheet, which form a
compact single-domain architecture with an α + β-fold.
The crystal structure of Ginkbilobin-2 was shown in
Figure 7 [18,88]. The positively charged surface of
ginkbilobin-2 might react with the negatively charged sur-
face of fungal cells to display its antifungal activity [87].
Ginkbilobin exhibited antifungal activity against Botrytis
cinerea, Mycosphaerella arachidicola, Fusarium oxysporum,
Rhizoctonia solani, and Coprinus comatus and antibacterial
activity against Staphylococcus aureus, Pseudomonas aeru-
ginosa, and Escherichia coli [85]. In addition, it inhibited
HIV-1 reverse transcriptase and proliferation of murine
splenocytes [85]. The pharmacology of ginkbilobin-2 should
be studied in the future.
Dioscorin from Dioscorea batatas
Tubers from the Dioscorea genus were widely used in CM
to relieve the menopausal syndrome [89]. A tuber storage
protein from Dioscorea batatas, dioscorin, was isolated
and purified by ammonium sulfate fractionation, DE-52
ion-exchange chromatography, and Sephadex G-75 col-
umn chromatography [90].
Dioscorea batatas dioscorin, a 32-kDa protein, protect
against airway damage due to the trypsin activity of dust
Figure 8 Crystal structure of the complex of trichosanthin of Trichosanthes kirilowii with adenine. A stands for chain of trichosanthin; 1
represents adenine.
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teins [90]. It prevented hydrogen peroxide-induced oxida-
tive damage via down regulating IL-8 secretion and
adhesion molecule expressions, and possibly activating
IκB in A549 human airway epithelial cells [91,92]. Dios-
corin also scavenged 1,1-diphenyl-2-picrylhydrazyl radicals
and capture hydroxyl radicals, indicating it had antioxi-
dant properties [93]. The immunomodulatory properties
of dioscorin included stimulation of cytokine production
and nitric oxide production, RAW 264.7 phagocytosis of
E. coli, and mitogenic effects on mouse splenocytes [94].
These properties were indicated by in vivo data from
dioscorin-treated BALB/c mice [95].
Trichosanthin from Trichosanthes kirilowii
The root of Trichosanthes kirilowii was used in CM for
treating lung heat (fei re) and inflammation [96]. A tricho-
santhin (TCS) was isolated from T. kirilowii root tubers by
acetone fractionation and CM-Sepharose ion-exchange
chromatography [97]. Recently, Arijit Mondal extracted
and purified TCS with three-phase partitioning (TPP),
which was cost-effective and environmental friendly [98].
TCS is a single-chain 24-kDa protein with 247 amino
acid residues including a 23-amino acid N-terminal sig-
nal peptide and a 19-amino acid C-terminal pro-peptide
[99-101]. TCS contains 12.2% α-helices, 16.3%, β-sheets,
51.4% turns, and 20.1% random curls. TCS is a type I
ribosome-inactivating protein, which inactivated ribo-
somes by site-specific cleavage of the single N–C glyco-
sidic bond and prevented the elongation factor from
binding to the 60S ribosomal subunit, resulting in arrest
of protein synthesis [102]. The mature protein is hom-
ologous to other ribosome-inactivating proteins (RIPs).The peptide SDDDMGFGLFD is related to the con-
served C-terminal elongation factor binding zone of the
ribosomal P protein and is similar to ricin A [103]. Add-
itionally, the crystal structure of the complex of tricho-
santhin with adenine was shown in Figure 8 [18,104].
Isoforms of TCS, α-, β- and γ-TCS, with similar bio-
chemical activities have been reported [105]. Also, Wang
et al. [106,107] constructed two mutants of TCS, RL28-
29CG and FYY163-165CSA in E.coli. TCS lowered serum
HIV-1 p24 antigen levels and increased CD4+ T cell num-
ber in HIV-1 infected patients [108,109]. TCS also inhib-
ited hepatitis B virus and tumor growth [110,111].
Additionally, TCS exhibited anti-cancer effects. TCS pro-
moted breast cell cancer cell line apoptosis in vitro and in
nude mice [112], and inhibited tumour migration in vitro
and angiogenesis in the aortic ring model without side ef-
fects [113]. TCS inhibited lung cancer proliferation and in-
duced apoptosis, and also enhanced the immunoreaction
by increasing the expression and interaction of tumor sup-
pressor in lung cancer 1 (TSLC1) and class I-restricted T
cell-associated molecule (CRTAM) [114]. TCS suppressed
nasopharyngeal carcinomas via inhibiting Notch signaling
and proliferation in vitro [115], as well as induced cell
death and inhibited telomerase activity in nude mice
[116]. Moreover, TCS possessed anti-HSV-1 property in
human epithelial carcinoma cell line HEp-2 via type II
apoptotic signaling after infection [117], and inhibiting the
activation of NF-κB and inducing p53-dependent apop-
tosis [118]. TCS was used to successfully cure 85% of 140
cases of ectopic pregnancy with higher beta-human chori-
onic gonadotropin [119].
TCS has limited clinical applications due to its major ad-
verse effects, including short plasma half-life, immunogenicity,
Wong et al. Chinese Medicine 2014, 9:19 Page 11 of 14
http://www.cmjournal.org/content/9/1/19and neurotoxicity [120,121]. However, TCS exhibited
less cytotoxicity than type II ribosome-inactivating pro-
teins, including abrin, ricin, etc. [120]. Researchers
employing recent advances in drug delivery technology
have reported that site-directed PEGylation of tricho-
santhin could decrease immunogenicity, and prolong
plasma half-life [7].
Future development
Research of bioactive proteins and peptides in CM is still
in the early stage of development. A number of them have
been isolated and characterized, but only a few are com-
mercially available as pharmaceuticals, such as Hirudin.
Advances in technologies would facilitate development of
protein pharmaceuticals in CM. Approaches to discovery
of the action mechanisms of proteins from CM would be
crucial to translate CM protein in synergistic proportions
into pharmaceutical for clinical use.
Conclusion
The bioactive proteins and peptides isolated from CM
have therapeutic potentials but further study and pharma-
ceutical development would be necessary for clinical use.
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